Literature DB >> 15688098

Carcinoma of the cardia: classification as esophageal or gastric cancer?

Burkhard H A von Rahden1, Marcus Feith, Hubert J Stein.   

Abstract

INTRODUCTION: The cardia is the anatomical borderland between the esophagus and stomach. Carcinomas of the cardia are regarded to share features of both, esophageal and gastric cancers. Controversy exists concerning their appropriate classification and whether these tumors comprise--in respect to tumor biology, pathophysiology as well as clinical features--an entirely separate entity. CLASSIFICATION: In order to distinguish cardia carcinomas from other adenocarcinomas arising within the vicinity of the esophagogastric junction, a classification system has been introduced from a surgical viewpoint, and is now well established and increasingly used worldwide. According to the topography of the main tumor mass, cardia carcinomas (AEG II) are distinguished from adenocarcinomas of the distal esophagus (AEG I) and subcardiac gastric cancers (AEG III). The tumor-node-metastasis (TNM) staging system by the International Union Against Cancer (UICC) does not provide a separate classification for tumors of the esophagogastric junction. The use of the classification for esophageal or for gastric cancers is recommended, irrespective of the elementary differences in the classification of lymphatic spread implemented herein. DISCUSSION: New aspects concerning this controversial debate are discussed based on current insights into the pathogenesis and the cellular origin of these entities. The controversies concerning the classification of cardia carcinomas and the failure of the current esophageal and gastric cancer staging systems to reflect the peculiarities of this entity accurately, present a strong argument in favor of a new classification system.

Entities:  

Mesh:

Year:  2004        PMID: 15688098     DOI: 10.1007/s00384-004-0646-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  21 in total

1.  Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus.

Authors:  J Theisen; H J Stein; H J Dittler; M Feith; C Moebius; W K H Kauer; M Werner; J R Siewert
Journal:  Surg Endosc       Date:  2002-01-09       Impact factor: 4.584

2.  Staging of oesophageal adenocarcinoma.

Authors:  R H Hardwick; G T Williams
Journal:  Br J Surg       Date:  2002-09       Impact factor: 6.939

3.  Barrett's esophagus: age, prevalence, and extent of columnar epithelium.

Authors:  A J Cameron; C T Lomboy
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

Review 4.  Cancer of the esophagogastric junction.

Authors:  H J Stein; M Feith; J R Siewert
Journal:  Surg Oncol       Date:  2000-07       Impact factor: 3.279

5.  Results of surgical treatment of adenocarcinoma of the gastric cardia.

Authors:  Giovanni de Manzoni; Corrado Pedrazzani; Felice Pasini; Alberto Di Leo; Emilia Durante; Gabriele Castaldini; Claudio Cordiano
Journal:  Ann Thorac Surg       Date:  2002-04       Impact factor: 4.330

Review 6.  Barrett's esophagus and Barrett's carcinoma.

Authors:  Burkhard H A von Rahden; Hubert J Stein; Jörg R Siewert
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

7.  Limited resection for early adenocarcinoma in Barrett's esophagus.

Authors:  H J Stein; M Feith; J Mueller; M Werner; J R Siewert
Journal:  Ann Surg       Date:  2000-12       Impact factor: 12.969

8.  Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification.

Authors:  W H Steup; P De Leyn; G Deneffe; D Van Raemdonck; W Coosemans; T Lerut
Journal:  J Thorac Cardiovasc Surg       Date:  1996-01       Impact factor: 5.209

Review 9.  [Carcinoma of the oesophagogastric junction and Barrett's esophagus: an almost clear oncologic model?].

Authors:  H J Stein; B H A von Rahden; H Höfler; J R Siewert
Journal:  Chirurg       Date:  2003-08       Impact factor: 0.955

10.  [Cardia cancer: attempt at a therapeutically relevant classification].

Authors:  J R Siewert; A H Hölscher; K Becker; W Gössner
Journal:  Chirurg       Date:  1987-01       Impact factor: 0.955

View more
  7 in total

Review 1.  Carcinoma of the gastroesophageal junction in Chinese patients.

Authors:  Qin Huang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

2.  An orthotopic nude mouse model for preclinical research of gastric cardia cancer.

Authors:  Sarah Bhargava; Birgit Hotz; Heinz J Buhr; Hubert G Hotz
Journal:  Int J Colorectal Dis       Date:  2008-09-30       Impact factor: 2.571

3.  Metastatic pattern in esophageal and gastric cancer: Influenced by site and histology.

Authors:  Moniek Hp Verstegen; Mitchell Harker; Carlijn van de Water; Jolanda van Dieren; Niek Hugen; Iris D Nagtegaal; Camiel Rosman; Rachel S van der Post
Journal:  World J Gastroenterol       Date:  2020-10-21       Impact factor: 5.742

4.  Effect of Marital Status on the Survival of Patients With Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Study.

Authors:  Sihan Wang; Liubo Chen; Dongdong Chen; Jian Chao; Yangliu Shao; Kejun Tang; Wenteng Chen
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

5.  A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.

Authors:  Y H Park; B-S Kim; B-Y Ryoo; S H Yang
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

6.  Metastatic spread in patients with gastric cancer.

Authors:  Matias Riihimäki; Akseli Hemminki; Kristina Sundquist; Jan Sundquist; Kari Hemminki
Journal:  Oncotarget       Date:  2016-08-09

7.  Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study.

Authors:  Liubo Chen; Kejun Tang; Sihan Wang; Dongdong Chen; Kefeng Ding
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.